Cilostazol attenuates kainic acid-induced hippocampal cell death
The Korean Journal of Physiology and Pharmacology
;
: 63-70, 2018.
Article
in English
| WPRIM
| ID: wpr-727937
ABSTRACT
Cilostazol is a selective inhibitor of type 3 phosphodiesterase (PDE3) and has been widely used as an antiplatelet agent. Cilostazol mediates this activity through effects on the cyclic adenosine monophosphate (cAMP) signaling cascade. Recently, it has attracted attention as a neuroprotective agent. However, little is known about cilostazol's effect on excitotoxicity induced neuronal cell death. Therefore, this study evaluated the neuroprotective effect of cilostazol treatment against hippocampal neuronal damage in a mouse model of kainic acid (KA)-induced neuronal loss. Cilostazol pretreatment reduced KA-induced seizure scores and hippocampal neuron death. In addition, cilostazol pretreatment increased cAMP response element-binding protein (CREB) phosphorylation and decreased neuroinflammation. These observations suggest that cilostazol may have beneficial therapeutic effects on seizure activity and other neurological diseases associated with excitotoxicity.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphorylation
/
Seizures
/
Adenosine Monophosphate
/
Cell Death
/
Cyclic AMP Response Element-Binding Protein
/
Neuroprotective Agents
/
Therapeutic Uses
/
Hippocampus
/
Kainic Acid
/
Neurons
Type of study:
Prognostic study
Limits:
Animals
Language:
English
Journal:
The Korean Journal of Physiology and Pharmacology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS